Long-term results of chemoradiotherapy for locally advanced esophageal cancer, using daily low-dose 5-fluorouracil and cis-diammine-dichloro-platinum (CDDP)
Autor: | Eisuke Abe, Tadashi Sugita, Mari Saito, Kunio Sakai, Tadayoshi Yamanoi, Keisuke Sasai, Ryuta Sasamoto, Emiko Tsuchida, Yasuo Matsumoto, Nobuko Yamana, Hiroo Sueyama, Takeshi Ito, Hideki Inakoshi |
---|---|
Rok vydání: | 2007 |
Předmět: |
Adult
Male Oncology medicine.medical_specialty Time Factors Esophageal Neoplasms medicine.medical_treatment Disease-Free Survival Drug Administration Schedule Low-dose chemotherapy Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Chemotherapy business.industry Dose fractionation Hematology General Medicine Middle Aged Esophageal cancer medicine.disease Survival Analysis Radiation therapy Treatment Outcome Chemotherapy Adjuvant Fluorouracil Toxicity Female Radiotherapy Adjuvant Surgery Dose Fractionation Radiation Cisplatin business Chemoradiotherapy Follow-Up Studies medicine.drug |
Zdroj: | International Journal of Clinical Oncology. 12:25-30 |
ISSN: | 1437-7772 1341-9625 |
Popis: | We evaluated the efficacy and toxicity of radiation combined with daily, low-dose protracted chemotherapy for locally advanced esophageal cancer.We analyzed data for 68 patients with locally advanced esophageal cancer, including 18 surgical candidates. Standard fractionation (total dose range, 60 to 70 Gy) was used for radiotherapy. The chemotherapy consisted of a daily 5-fluorouracil dose of 250 mg/m2, with a cis-diammine-dichloro-platinum dose of 3 mg/m2 administered on radiotherapy days.Sixty-four patients (94%) received at least 60 Gy. Grade 3 acute hematological toxicity was observed in 13 (19%) patients; there was no grade 4 hematological toxicity. Complete response, partial response, no change, and progressive disease were obtained in 22, 35, 7, and 4 patients, respectively. Minimum follow-up for surviving patients was 45 months. Locoregional progression-free rates at 3 and 5 years were 47% and 47%. Four patients died of late cardiac toxicity; the primary site for all 4 patients was the middle thoracic esophagus. Overall survival rates at 2, 3, and 5 years were 40%, 32%, and 20%. The 3- and 5-year survival rates in patients with T2-3M0 disease were 43% and 27%, and the rates were 24% and 15% in patients with T4/M1.Given the large proportion of patients in this study with inoperable disease (roughly three quarters), our treatment seemed to provide equivalent efficacy and less hematological toxicity than standard-dose chemoradiotherapy. |
Databáze: | OpenAIRE |
Externí odkaz: |